12 Health Care Stocks Moving In Monday's After-Market Session
Actuate Therapeutics Inc ACTU
$0.69
▼ -6.82%
($-0.05)
⬇️ Below Yest. Low
🎈 Low Float
Open
$0.74
Prev Close
$0.74
Day Range
$0.68 – $0.75
52W Range
$0.61 – $8.49
Market Cap
$16.47M
Beta
1.62
EPS (TTM)
$-0.89
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2024-08-13 |
| Shares Out. | 23,930,000 |
| Website | actuatetherapeutics.com/ ↗ |
| Phone | 18479864190 |
| Employees | 12 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$4.9M |
| Free Cash Flow | -$19.8M |
| Total Assets | $5.2M |
| Total Liabilities | $4.2M |
| Equity | $989,152 |
About Actuate Therapeutics Inc
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
Actuate Therapeutics Inc is a publicly traded company under the ticker symbol ACTU on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
9 analysts (2026-09-01)